Janssen-Cilag treatment STELARA yields positive results during trial
22 January 2010 00:00 in Pharmaceutical Company Product News
Janssen-Cilag has revealed that its moderate to severe plaque psoriasis therapy STELARA (ustekinumab) yielded positive results during a recent phase III clinical trial.
The treatment demonstrated higher safety and efficacy than current treatment etanercept and may offer an alternative to those who have not responded to the latter drug.
During the trial, 68 per cent and 74 per cent of patients receiving subcutaneous injections of STELARA at respective doses of 45 mg and 90 mg at weeks 0 and 4 achieved at least a 75 per cent reduction in psoriasis at week 12.
Lead investigator of the trial and professor at the University of Manchester Chris Griffiths said: "We observed a substantial proportion of patients achieving high levels of skin clearance with ustekinumab, both through the study's primary endpoint at week 12 and following crossover from etanercept."
Cilag was founded in 1936 and merged with Janssen Pharmaceutica in 1994 to establish the current organisation.
Janssen-Cilag has more than 6,000 employees in Europe, who are working towards the development of innovative treatments.
Other news stories from 22/01/2010
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency